Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase Ila Multiple Basket Study (vol 36, pg 536, 2018)

被引：0
|
作者：
Burris, Howard A.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.18.02263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：360 / 360
页数：1
相关论文
共 50 条
  • [21] Preliminary findings from a phase I, open-label, dose-finding study of SNB-101 in patients with advanced solid tumors
    Sang, Y. B.
    Kim, Y.
    Lee, M. A.
    Rha, S. Y.
    Jung, M.
    Lee, C-K.
    Park, Y. H.
    Heo, D.
    Kim, A.
    Kim, J.
    Kim, J-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S474 - S474
  • [22] Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
    Thein, Kyaw Zin
    Piha-Paul, Sarina A.
    Tsimberidou, Apostolia
    Karp, Daniel D.
    Janku, Filip
    Zarifa, Abdulrazzak
    Shah, Jatin
    Milton, Denai R.
    Bean, Stacie
    McQuinn, Lacey
    Gong, Jing
    Colen, Rivka
    Carter, Brett W.
    Subbiah, Vivek
    Ogbonna, Deby C.
    Pant, Shubham
    Meric-Bernstam, Funda
    Naing, Aung
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1357 - 1365
  • [23] Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a Phase III randomized, open-label, multicenter trial
    Motzer, R.
    Nosov, D.
    Eisen, T.
    Bondarenko, I.
    Lesovoy, V.
    Lipatov, O.
    Tomczak, P.
    Lyulko, O.
    Alyasova, A.
    Harza, M.
    Kogan, M.
    Alexeev, B. Y.
    Sternberg, C. N.
    Szczylik, C.
    Zhang, J.
    Strahs, A.
    Esteves, B.
    Slichenmyer, W.
    Berkenblit, A.
    Hutson, T. E.
    BJU INTERNATIONAL, 2012, 110 : 14 - 14
  • [24] An open-label, multi-center phase I study of the safety and tolerability of the novel immunomodulatory agent PG545 in subjects with advanced solid tumors.
    Dredge, Keith
    Brennan, Todd
    Brown, Michael Paul
    Lickliter, Jason D.
    Barnpton, Darryn
    Hammond, Edward
    Lin, Liwen
    Yang, Yiping
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] A phase II, open-label, multicenter, basket study of the ATR kinase inhibitor ART0380 administered orally as monotherapy to patients with biologically selected advanced or metastatic solid tumors (ARTIST)
    Aghajanian, Carol
    Washington, Christina
    Moore, Kathleen
    Krivak, Thomas
    Mathews, Cara
    Philip, Tony
    Konecny, Gottfried
    Fleming, Gini
    Martin, Niall
    Smith, Graeme
    Harrop, Bryony
    Millward, Helen
    Skelton, Samantha
    Little, Nicola
    Headley, Desiree
    Smith, Ian
    Konstantinopoulos, Panagiotis
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S296 - S297
  • [26] Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study (vol 8, e000437, 2020)
    Shen, L.
    Guo, J.
    Zhang, Q.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [27] Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
    Kyaw Zin Thein
    Sarina A. Piha-Paul
    Apostolia Tsimberidou
    Daniel D. Karp
    Filip Janku
    Abdulrazzak Zarifa
    Jatin Shah
    Denái R. Milton
    Stacie Bean
    Lacey McQuinn
    Jing Gong
    Rivka Colen
    Brett W. Carter
    Vivek Subbiah
    Deby C. Ogbonna
    Shubham Pant
    Funda Meric-Bernstam
    Aung Naing
    Investigational New Drugs, 2022, 40 : 461 - 461
  • [28] Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.
    Motzer, Robert John
    Nosov, Dmitry
    Eisen, Tim
    Bondarenko, Igor N.
    Lesovoy, Vladmir
    Lipatov, Oleg N.
    Tomczak, Piotr
    Lyulko, Alexey A.
    Alyasova, Anna
    Harza, Mihai
    Kogan, Mikhail
    Alexeev, Boris Y.
    Sternberg, Cora N.
    Szczylik, Cezary
    Zhang, Joshua
    Strahs, Andrew Louis
    Esteves, Brooke
    Slichenmyer, William J.
    Berkenblit, Anna
    Hutson, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions
    Drilon, Alexander
    Sankhala, Kamalesh Kumar
    Liu, Stephen V.
    Cho, Byoung Chul
    Blakely, Collin
    Chee, Cheng E.
    Fakih, Marwan
    Polikoff, Jonathan
    Hornby, Zachary
    Schechet, Lisa
    Luo, David
    Maneval, Edna Chow
    Multani, Pratik S.
    Doebele, Robert C.
    CANCER RESEARCH, 2017, 77
  • [30] AGADIR: A basket multicenter open-label phase II study evaluating the first in class TLR7/8 agonist BDB001 in combination with atezolizumab and stereotactic body radiation therapy in patients with advanced solid tumors
    Italiano, A.
    Bergouignan, C. Coutzac
    Pasquier, D.
    Rochigneux, P.
    Sablin, M. P.
    Gomez-Roca, C. A.
    Ghiringhelli, F.
    Metges, J-P.
    Toulmonde, M.
    Cousin, S.
    Pernot, S.
    Auzanneau, C.
    Lortal, B.
    Kind, M.
    Sargos, P.
    Batard, S.
    Petit, A.
    Gillon, P.
    Albert, S.
    Pulido, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S898 - S898
12345